Related by context. Frequent words. (Click for all words.) 69 cytogenetic response 69 evaluable 68 complete remissions 68 RECIST criteria 68 patients evaluable 66 evaluable patients 66 HSCT 66 Secondary endpoints include 66 irbesartan 65 neoadjuvant chemotherapy 65 mg QD 65 plus dexamethasone 65 Secondary endpoints included 64 plus prednisone 64 RECIST 64 Secondary endpoints 64 FOLFIRI 64 Fludara 63 Lenalidomide 63 DOXIL 63 metastatic renal cell carcinoma 63 relapsed refractory multiple myeloma 62 neoadjuvant 62 chemoradiotherapy 62 XELOX 62 nab paclitaxel 62 Taxotere ® 62 plus gemcitabine 62 GvHD 62 active comparator 61 mg kg dose 61 dose cohorts 61 virologic failure 61 sustained virologic response 61 FOLFOX 61 metastatic hormone refractory 61 achieved statistical significance 61 plus methotrexate 61 octreotide 61 Amrubicin 61 refractory multiple myeloma 61 biologic therapy 61 dacarbazine 61 mcg kg 61 prespecified 61 EBRT 61 mycophenolate mofetil 61 median PFS 60 PROMACTA 60 glatiramer acetate 60 azacitidine 60 serum phosphorus 60 tipranavir 60 decitabine 60 tumor lysis syndrome 60 topotecan 60 DMARD 60 peginterferon alfa 2b 60 Torisel 60 peginterferon 60 TORISEL 60 haematological 60 adalimumab 60 peg IFN 60 annualized relapse 60 virologic response 60 monotherapy 60 plus ribavirin 60 abiraterone acetate 60 Irinotecan 60 Median survival 60 temsirolimus 60 tumor regression 60 pancreatic insufficiency 60 Erlotinib 60 SCH # 60 HCV infected 59 ACR# [002] 59 Gemcitabine 59 docetaxel 59 free survival PFS 59 relapsed refractory 59 tocilizumab 59 Phase 2a trial 59 HER2 positive metastatic breast 59 tamoxifen therapy 59 neoadjuvant therapy 59 placebo p = 59 composite endpoint 59 secondary efficacy endpoints 59 coinfected 59 Jevtana 59 mcg dose 59 ponatinib 59 noninferiority 59 Pivotal Phase III 59 tumor shrinkage 59 mg BID 59 Solid Tumors 59 dasatinib 59 administered subcutaneously